Literature DB >> 21710128

High APOE epsilon 4 allele frequencies associated with Alzheimer disease in a Tunisian population.

Afef Achouri Rassas1, Hela Mrabet Khiari, Sondes Hadj Fredj, Safa Sahnoun, Hend Batti, Nouria Oudiaa Zakraoui, Aroua Cherif, Nadia Anane, Nadia Ben Ali, Taieb Messaoud, Amel Mrabet.   

Abstract

The goal of the study was to examine the Apolipoprotein E (APOE) genotypes in a Tunisian sample of patients with Alzheimer disease (AD) and normal controls, and to compare the results with the findings from the literature. A hospital-based case-control study of two groups (58 patients with AD, 71 controls) was conducted. Patients received a detailed clinical history, neurological examination, neuropsychological testing and brain imaging. A neurological examination and the Arabic version of the Mini-Mental State Examination were made for controls. Genotyping was performed using the PCR restriction fragment length polymorphism (PCR-RFLP) method. There were no statistical differences in age (p = 0.05) and gender (p = 0.046) between the two groups. The APOE ε4/4 genotype was over represented in the AD group in comparison with the controls (13.3 vs. 2.8%). A significant increased risk of AD among APOE ε4 allele carriers was observed. The odds ratio for the association of AD patients with homozygous and heterozygous ε4 allele was, respectively, 5.40 (1.35-21.48) and 2.90 (1.27-6.62). Our results in addition to previously published genetic studies suggest that AD disease is multifactor in origin. Ethnicity, genetic and environmental factors contribute to AD risk in different ethnic groups.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21710128     DOI: 10.1007/s10072-011-0663-8

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  35 in total

1.  Association between apolipoprotein E polymorphism and Alzheimer's disease in Koreans.

Authors:  K W Kim; J H Jhoo; K U Lee; D Y Lee; J H Lee; J Y Youn; B J Lee; S H Han; J I Woo
Journal:  Neurosci Lett       Date:  1999-12-31       Impact factor: 3.046

2.  A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease.

Authors:  J C Lambert; F Pasquier; D Cottel; B Frigard; P Amouyel; M C Chartier-Harlin
Journal:  Hum Mol Genet       Date:  1998-03       Impact factor: 6.150

Review 3.  Genetic susceptibility factors for Alzheimer's disease.

Authors:  F Richard; P Amouyel
Journal:  Eur J Pharmacol       Date:  2001-01-19       Impact factor: 4.432

4.  APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians.

Authors:  Oye Gureje; Adesola Ogunniyi; Olusegun Baiyewu; Brandon Price; Frederick W Unverzagt; Rebecca M Evans; Valerie Smith-Gamble; Kathleen A Lane; Sujuan Gao; Kathleen S Hall; Hugh C Hendrie; Jill R Murrell
Journal:  Ann Neurol       Date:  2006-01       Impact factor: 10.422

5.  APO E polymorphism in Spanish and Moroccan populations.

Authors:  N Valveny; E Esteban; M Kandil; P Moral
Journal:  Clin Genet       Date:  1997-05       Impact factor: 4.438

6.  Genetic study of Sardinian patients with Alzheimer's disease.

Authors:  Paola Piscopo; Antonella Manfredi; Lorenzo Malvezzi-Campeggi; Alessio Crestini; Ornella Spadoni; Rossella Cherchi; Emiliano Deiana; Maria Rita Piras; Annamaria Confaloni
Journal:  Neurosci Lett       Date:  2006-01-19       Impact factor: 3.046

Review 7.  Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease.

Authors:  Davide Seripa; Francesco Panza; Marilisa Franceschi; Grazia D'Onofrio; Vincenzo Solfrizzi; Bruno Dallapiccola; Alberto Pilotto
Journal:  Ageing Res Rev       Date:  2009-07       Impact factor: 10.895

Review 8.  Underexpression of the apolipoprotein E2 and E4 alleles in the Greek Cypriot population of Cyprus.

Authors:  M A Cariolou; A Kokkofitou; P Manoli; S Christou; A Karagrigoriou; L Middleton
Journal:  Genet Epidemiol       Date:  1995       Impact factor: 2.135

9.  Apo E allele frequencies in Alzheimer's disease, Lewy body dementia, Alzheimer's disease with cerebrovascular disease and vascular dementia.

Authors:  C Bétard; Y Robitaille; M Gee; D Tiberghien; D Larrivée; P Roy; J A Mortimer; D Gauvreau
Journal:  Neuroreport       Date:  1994-10-03       Impact factor: 1.837

Review 10.  Apolipoprotein E genotyping in Alzheimer's disease. National Institute on Aging/Alzheimer's Association Working Group.

Authors: 
Journal:  Lancet       Date:  1996-04-20       Impact factor: 79.321

View more
  10 in total

Review 1.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

2.  Association between Alzheimer disease and the -491T allele of regulatory region polymorphism of Apolipoprotein E in a Tunisian population.

Authors:  Afef Achouri-Rassas; Sondes Hadj Fredj; Hela Mrabet Khiari; Amina Bibi; Hajer Siala; Amel Mrabet; Taieb Messaoud
Journal:  Neurochem Res       Date:  2013-12-11       Impact factor: 3.996

3.  No association between an intronic polymorphism in the presenilin-1 gene and Alzheimer disease in a Tunisian population.

Authors:  Afef Achouri Rassas; Sondess Hadj Fredj; Hela Mrabet Khiari; Safa Sahnoun; Amina Bibi; Hajer Siala; Amel Mrabet; Taieb Messaoud
Journal:  J Neural Transm (Vienna)       Date:  2013-01-31       Impact factor: 3.575

4.  Association between ACE polymorphism, cognitive phenotype and APOE E4 allele in a Tunisian population with Alzheimer disease.

Authors:  Afef Achouri-Rassas; Nadia Ben Ali; Aroua Cherif; Saloua Fray; Hajer Siala; Nouria Oudiaa Zakraoui; Sondes Hadj-Fredj; Mariem Kechaou; Nadia Anane; Slim Echebi; Taieb Messaoud; Samir Belal
Journal:  J Neural Transm (Vienna)       Date:  2015-10-12       Impact factor: 3.575

Review 5.  Exercise, APOE genotype, and the evolution of the human lifespan.

Authors:  David A Raichlen; Gene E Alexander
Journal:  Trends Neurosci       Date:  2014-03-30       Impact factor: 13.837

Review 6.  Neurogenomics in Africa: Perspectives, progress, possibilities and priorities.

Authors:  Rufus O Akinyemi; Mayowa O Owolabi; Tolulope Oyeniyi; Bruce Ovbiagele; Donna K Arnett; Hemant K Tiwari; Richard Walker; Adesola Ogunniyi; Raj N Kalaria
Journal:  J Neurol Sci       Date:  2016-05-06       Impact factor: 3.181

7.  Protective effect of the APOE-e3 allele in Alzheimer's disease.

Authors:  B V P de-Almada; L D de-Almeida; D Camporez; M V D de-Moraes; R L Morelato; A M S Perrone; L Belcavello; I D Louro; F de-Paula
Journal:  Braz J Med Biol Res       Date:  2011-11-08       Impact factor: 2.590

8.  Serum calreticulin is a negative biomarker in patients with Alzheimer's disease.

Authors:  Qiao Lin; Yunpeng Cao; Jie Gao
Journal:  Int J Mol Sci       Date:  2014-11-25       Impact factor: 5.923

9.  APOE Promoter Polymorphism-219T/G is an Effect Modifier of the Influence of APOE ε4 on Alzheimer's Disease Risk in a Multiracial Sample.

Authors:  Kyu Yeong Choi; Jang Jae Lee; Tamil Iniyan Gunasekaran; Sarang Kang; Wooje Lee; Jangho Jeong; Ho Jae Lim; Xiaoling Zhang; Congcong Zhu; So-Yoon Won; Yu Yong Choi; Eun Hyun Seo; Seok Cheol Lee; Jungsoo Gim; Ji Yeon Chung; Ari Chong; Min Soo Byun; Sujin Seo; Pan-Woo Ko; Ji-Won Han; Catriona McLean; John Farrell; Kathryn L Lunetta; Akinori Miyashita; Norikazu Hara; Sungho Won; Seong-Min Choi; Jung-Min Ha; Jee Hyang Jeong; Ryozo Kuwano; Min Kyung Song; Seong Soo A An; Young Min Lee; Kyung Won Park; Ho-Won Lee; Seong Hye Choi; Sangmyung Rhee; Woo Keun Song; Jung Sup Lee; Richard Mayeux; Jonathan L Haines; Margaret A Pericak-Vance; I L Han Choo; Kwangsik Nho; Ki-Woong Kim; Dong Young Lee; SangYun Kim; Byeong C Kim; Hoowon Kim; Gyungah R Jun; Gerard D Schellenberg; Takeshi Ikeuchi; Lindsay A Farrer; Kun Ho Lee; Alzheimer's Disease Neuroimaging Initative
Journal:  J Clin Med       Date:  2019-08-16       Impact factor: 4.241

10.  Decreased expression of the APOA1-APOC3-APOA4 gene cluster is associated with risk of Alzheimer's disease.

Authors:  Qiao Lin; Yunpeng Cao; Jie Gao
Journal:  Drug Des Devel Ther       Date:  2015-09-29       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.